Novartis

Novartis Launches First-of-Its-Kind Not-for-Profit Portfolio of Medicines for Symptomatic Treatment of COVID-19

Press Release
  • Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptoms
  • Portfolio will be sold at zero-profit to governments in up to 791 eligible countries during the pandemic and until a vaccine or curative treatment is available
  • Early access to treatment for managing  COVID-19 symptoms is critical to preventing healthcare system overload

New Agreements to Expand Access to 20 Lifesaving Cancer Medicines for Countries in Sub-Saharan Africa and Asia

Cancer Access Partnership is expected to result in a 59 percent savings on procured cancer medicines
Press Release

June 29, 2020 /3BL Media/ - The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) today announced agreements with pharmaceutical companies Pfizer, Novartis, and Mylan to expand access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59 percent for medicines procured through the agreements.

Novartis Expands Africa Sickle Cell Disease Program to Uganda and Tanzania

Summary: 
  • New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care
  • Program continues progress in Ghana with more than 2000 patients being treated with hydroxyurea in 11 treatment centers across the country
  • Novartis plans to roll the program out to a total of 10 African countries by 2022
  • Approximately 1 000 children in Africa are born with SCD every day and more than half will die before they reach the age of five1
Press Release
  • New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care
  • Program continues progress in Ghana with more than 2000 patients being treated with hydroxyurea in 11 treatment centers across the country
  • Novartis plans to roll the program out to a total of 10 African countries by 2022
  • Approximately 1 000 children in Africa are born with SCD every day and more than half will die before they reach the age of five1

Impact Makers: Novartis

Maximizing Technology, Time & Teamwork for Critical Impact, Now
Blog

No question, the last eight weeks have been tough on everyone. As a pharma company, Novartis felt a duty to respond and call to be part of the solution. The Novartis purpose is to re-imagine medicine to improve and extend people's lives. The Novartis' purpose statement is aligned with four key areas: holding themselves to the highest ethical standards, being part of the solution on pricing and access to medicines, helping tackle global health challenges, and being a responsible citizen. 

Fondation Botnar and Novartis Support EDCTP Fellowships on Child and Adolescent Health

Press Release

May 6, 2020 /3BL Media/ - Fondation Botnar and Novartis will support research capacity development in sub-Saharan Africa within the framework of EDCTP’s 2020 Career Development Fellowships. Collectively, the two organisations will contribute up to a maximum of €2.25 million to the initial EDCTP call budget of €1.5 million. Their investments will support successful proposals to conduct research on child and adolescent health with a focus on the interaction between poverty-related infectious diseases and non-communicable diseases.

The Role of Managed Access in a Time of Crisis: A Case Study on How Novartis is Making Critical Impact – Webinar 5/20 at 11am ET

Blog

The impact of the Coronavirus (COVID-19) outbreak continues to disrupt our society as we know it, for many becoming a matter of life or death. While there is ongoing research & development work to identify solutions to address the pandemic, managed or expanded access to medicines is now more critical than ever to help address some of the urgent patient needs at various COVID-19 epicenters.  

Novartis US Foundation Supports Telehealth Programs to Provide Access to Care for New Jersey’s Most Vulnerable Communities

Summary: 
  • Partnership with NJPCA, which represents 23 community health centers in NJ, funded 5 telehealth pilots; programs serving as role models for centers across state
  • The Grant enabled NJ community health centers to quickly implement telehealth to maintain continuity of care for underserved communities, especially critical during the current COVID-19 pandemic  
  • Novartis US Foundation supports programs to reimagine healthcare through use of digital tools to reduce barriers to care
Press Release
  • Partnership with NJPCA, which represents 23 community health centers in NJ, funded 5 telehealth pilots; programs serving as role models for centers across state
  • The Grant enabled NJ community health centers to quickly implement telehealth to maintain continuity of care for underserved communities, especially critical during the current COVID-19 pandemic  
  • Novartis US Foundation supports programs to reimagine healthcare through use of digital tools to reduce barriers to care

Novartis to Sponsor Large Clinical Trial of Hydroxychloroquine in Hospitalized COVID-19 Patients

Summary: 
  • Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease
     
  • Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease 
  • Company will also make its hydroxychloroquine intellectual property available to support broad access if medicine is approved for COVID-19
  • Study complements Novartis commitment to donate up to 130 million doses of hydroxychloroquine globally to support the COVID-19 pandemic response
  • Novartis has a broad COVID-19 research and development commitment, including multiple large sponsored and investigator initiated clinical trials of its medicines
Press Release
  • Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease
     
  • Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease 
  • Company will also make its hydroxychloroquine intellectual property available to support broad access if medicine is approved for COVID-19
  • Study complements Novartis commitment to donate up to 130 million doses of hydroxychloroquine globally to support the COVID-19 pandemic response
  • Novartis has a broad COVID-19 research and development commitment, including multiple large sponsored and investigator initiated clinical trials of its medicines

Celebrating the First World Chagas Disease Day

Press Release

For the first time in history, the global health community is preparing to celebrate World Chagas Disease Day. Novartis is joining the global movement to raise visibility and awareness of patients with Chagas disease1.

Pages

Subscribe to Novartis